Cybin Inc. Common Shares (NY:CYBN)

8.280 UNCHANGED

Last Price Updated: 8:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

41 42 Next >

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Commencement of Kernel Flow(R) Feasibility Study, Marking Exciting Moment for Psychedelic Drug Development

March 31, 2022

Via Investor Brand Network

Cybin Begins Study Using Kernel Flow Headsets To Measure Ketamine's Effects On The Brain ↗

March 31, 2022

The first study visit to measurethe psychedelic effects of ketamine in the cerebral cortex blood flowis underway, ...

Via Benzinga

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

March 31, 2022

From Cybin Inc.

Via Business Wire

Cybin Subsidiary Achieves Milestone ↗

March 25, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Cybin Planning Pilot Study Of CYB004 ↗

March 22, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Revive Therapeutics, Allied Among Top Psychedelic Movers Of Today ↗

March 30, 2022

GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 4.22% at $0.46

Via Benzinga

Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Milestone In CYB003 Program ↗

March 30, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Milestone in CYB003 Program

March 30, 2022

Via Investor Brand Network

Psychedelic Stock Gainers And Losers From March 29, 2022 ↗

March 29, 2022

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 9.05% at $5.42

Via Benzinga

Cybin Completes In Vivo Preclinical Studies For Major Depressive Disorder ↗

March 29, 2022

Cybin Inc.(NYSE: CYBN) announced that its in vivo preclinical studies evaluating the proprietary drug CYB003 are completed. ...

Via Benzinga

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Significant Milestone Toward Advancing CYB003 Program

March 29, 2022

Via Investor Brand Network

New Research Reveals How Psychedelics Are Helping Combat Mental Illness

March 29, 2022

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 29, 2022 – Mental health cases are continuing to rise and are taking a serious toll on the healthcare system. Luckily,...

Via FinancialNewsMedia

Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial

March 29, 2022

From Cybin Inc.

Via Business Wire

Mindset Pharma, Small Pharma Among Top Psychedelic Movers Of Today ↗

March 28, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 8.24% at $0.18

Via Benzinga

Psychedelic Stock Gainers And Losers From March 25, 2022 ↗

March 25, 2022

GAINERS: Allied (OTC:

Via Benzinga

Cybin (NEO: CYBN) (NYSE American: CYBN) Subsidiary Achieves Milestone

March 25, 2022

Via Investor Brand Network

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Subsidiary Achieves Milestone Outlined in Contribution Agreement

March 25, 2022

Via Investor Brand Network

Cybin Announces Additional Adelia Milestone Achievement

March 25, 2022

From Cybin Inc.

Via Business Wire

Allied, Field Trip Health Among Top Psychedelic Movers Of Today ↗

March 24, 2022

GAINERS: Allied (OTC:

Via Benzinga

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Commences Participant Recruitment in Feasibility Study Using Kernel Flow Technology

March 24, 2022

Via Investor Brand Network

Five Companies Developing Second Generation Psychedelics For Mental Health ↗

March 24, 2022

Along with the psychedelic renaissance came a new type of drug: second generation psychedelics. Developed from classic psychedelics ...

Via Benzinga

Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants

March 24, 2022

From Cybin Inc.

Via Business Wire

Psychedelic Stock Gainers And Losers From March 23, 2022 ↗

March 23, 2022

GAINERS: Compass Pathways (NASDAQ:

Via Benzinga

Mindset Pharma, Compass Pathways Among Top Psychedelic Movers Of Today ↗

March 22, 2022

GAINERS: Mind Medicine (NASDAQ:

Via Benzinga

Cybin (NYSE American: CYBN) (NEO: CYBN) Planning Pilot Study of CYB004

March 22, 2022

Via Investor Brand Network

Topics Intellectual Property

Field Trip Health, Mindset Pharma Among Top Psychedelic Movers Of Today ↗

March 21, 2022

GAINERS: Field Trip Health (NASDAQ:

Via Benzinga

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Planning Pilot Study of CYB004, Pursuing Multiple Opportunities to Secure, Support Patent Position for R&D

March 21, 2022

Via Investor Brand Network

Topics Intellectual Property

Psychedelic Compounds-Based Drug Stocks Index Bounces Back ↗

March 20, 2022

Updating the stock performances of the 13 constituents in our Pure-Play Marijuana and Psychedelic Compounds-Based Drug Stocks Index: up last week but still down 32% YTD.

Via Talk Markets

Field Trip Health, Allied Among Top Psychedelic Movers Of Today ↗

March 18, 2022

GAINERS: Field Trip Health (NASDAQ:

Via Benzinga

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) on Leading Edge of Development of Psychedelics as Public Support Grows

March 17, 2022

Via Investor Brand Network

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.